Jonathan P. Laye
YOU?
Author Swipe
View article: Supplementary Table 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Table 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 52K, Lack of CYP1 induction by the chloromethylpyrroloindoline ICT2700
View article: Supplementary Figure 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Figure 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 120K, Representative CYP1A1 activity of the EJ138 bladder cell line and EJ138-1A1 bladder cell line, determined by measurement of Ethoxyresorufin O-de-ethylation
View article: Data from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Data from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
We identify cytochrome P450 1A1 (CYP1A1) as a target for tumor-selective drug development in bladder cancer and describe the characterization of ICT2700, designed to be metabolized from a prodrug to a potent cytotoxin selectively by CYP1A1…
View article: Supplementary Figure 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Figure 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 107K, In vivo metabolic profile of tumour and liver after administration of ICT2700 to CYP1A1 tumor-bearing mice
View article: Supplementary Table 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Table 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 85k, Expression of CYP1A1 protein in human transitional cell carcinoma (TCC) of the bladder by immunohistochemical analyses.
View article: Supplementary Table 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Table 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 85k, Expression of CYP1A1 protein in human transitional cell carcinoma (TCC) of the bladder by immunohistochemical analyses.
View article: Supplementary Methods from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Methods from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 109K, Methodology for analysis of CYP1 gene and protein expression,Detection of DNA-damage induced gamma-H2AX protein expression, and analysis of ICT2700 metabolism in mouse and human liver ex vivo
View article: Supplementary Figure 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Figure 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 107K, In vivo metabolic profile of tumour and liver after administration of ICT2700 to CYP1A1 tumor-bearing mice
View article: Supplementary Figure 3 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Figure 3 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 156K, Chromatogram of metabolite profile of ICT2700 incubated with human ex vivo liver microsomes demonstrating there is no evidence for the appearance of the cytotoxic metabolite ICT2740
View article: Supplementary Methods from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Methods from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 109K, Methodology for analysis of CYP1 gene and protein expression,Detection of DNA-damage induced gamma-H2AX protein expression, and analysis of ICT2700 metabolism in mouse and human liver ex vivo
View article: Supplementary Figure 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Figure 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 120K, Representative CYP1A1 activity of the EJ138 bladder cell line and EJ138-1A1 bladder cell line, determined by measurement of Ethoxyresorufin O-de-ethylation
View article: Supplementary Table 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Table 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 52K, Lack of CYP1 induction by the chloromethylpyrroloindoline ICT2700
View article: Supplementary Figure 3 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Supplementary Figure 3 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
PDF file - 156K, Chromatogram of metabolite profile of ICT2700 incubated with human ex vivo liver microsomes demonstrating there is no evidence for the appearance of the cytotoxic metabolite ICT2740
View article: Data from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Data from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Open
We identify cytochrome P450 1A1 (CYP1A1) as a target for tumor-selective drug development in bladder cancer and describe the characterization of ICT2700, designed to be metabolized from a prodrug to a potent cytotoxin selectively by CYP1A1…
View article: Supplementary Data 1 from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
Supplementary Data 1 from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma Open
Gene lists per immune cell type after successive filtration steps.
View article: Data from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
Data from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma Open
The immune response to melanoma improves the survival in untreated patients and predicts the response to immune checkpoint blockade. Here, we report genetic and environmental predictors of the immune response in a large primary cutaneous m…
View article: Supplementary Data 2 from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
Supplementary Data 2 from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma Open
List of 70 genes shared between the signature used to generate the three immune subgroups in this study and the TCGA signature as well as tables of additional results from the analysis of the 3 immune subgroups: Genes and pathways upregula…
View article: Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma Open
Supplementary Methods
View article: Supplementary Tables from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Supplementary Tables from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
Supplementary Tables 1-8
View article: Supplementary methods and results from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
Supplementary methods and results from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma Open
Additional information on methods used and supplementary figures and tables. Figure S1: Schematic summary of consensus clustering; Figure S2: Comparison of the newly obtained immune subgroups with two published melanoma molecular signature…
View article: Supplementary Figure 4 from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Supplementary Figure 4 from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
Comparison of CD3 positive immune infiltrate in murine lungs
View article: Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma Open
Supplementary Methods
View article: Data from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Data from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
1α,25-Dihydroxyvitamin D3 signals via the vitamin D receptor (VDR). Higher serum vitamin D is associated with thinner primary melanoma and better outcome, although a causal mechanism has not been established. As patients with melanoma comm…
View article: Supplementary Figure 3 from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Supplementary Figure 3 from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
Estimation of VDR expression in murine melanoma cells using Western blot and qRT-PCR
View article: Supplementary Figure 4 from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Supplementary Figure 4 from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
Comparison of CD3 positive immune infiltrate in murine lungs
View article: Supplementary Methods from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Supplementary Methods from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
Supplementary methods
View article: Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma Open
Supplementary Figures and tables
View article: Supplementary Data 1 from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
Supplementary Data 1 from Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma Open
Gene lists per immune cell type after successive filtration steps.
View article: Data from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Data from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
1α,25-Dihydroxyvitamin D3 signals via the vitamin D receptor (VDR). Higher serum vitamin D is associated with thinner primary melanoma and better outcome, although a causal mechanism has not been established. As patients with melanoma comm…
View article: Legend for Supplementary tables from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Legend for Supplementary tables from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity Open
Legend for Supplementary tables